Get started

Stockstrading

Purchase Order for HybridTech Armor© Panels for Aircraft CarrierCPS Technologies Corporation receives Purchase Order for HybridTech Armor© Panels for Aircraft Carrier CPSH today announced receipt of a purchase order for HybridTech Armor© Panels to be installed as the strike face of advanced ballistic shields to support U.S. Navy CVN class ships. The purchase order covers panels to equip all crew-served weapons stations on one aircraft carrier. We have received a $28.7 million IDIQ contract from the Navy to address the aircraft carrier fleet, with an initial delivery order for the first aircraft carrier.” finance.yahoo.com
NASDAQ:CPSH
by AlenCiken
1
Acquires Exclusive Rights to Rare Earth Element InnovationsAmerican Resources Corporation Acquires Exclusive Rights to Purdue University's Rare Earth Element Innovations, Critical for Clean Energy Technologies. An environmentally safer method of rare earth and other critical material separation and purification using ligand-assisted chromatography for coal, coal byproducts, recycled permanent magnets and Lithium Ion batteries. Announced that, with the addition of Hasler Ventures LLC, the Company has licensed ligand assisted displacement ("LAD") chromatography patents and knowhow to further expanded its capability in environmentally friendly separation and purification of rare earth elements. These exclusive patents and technologies, developed at Purdue University, are specific to the processing of separated and pure rare earth metals and critical elements from coal byproducts, recycled permanent magnets and lithium-ion batteries. Rare earth elements (REEs) include the 15 elements in the lanthanide series plus scandium (Sc) and yttrium (Y). They are essential ingredients for magnets, metal alloys, polishing powders, catalysts, ceramics, and phosphors, which are important for high-technology and clean energy applications. The global REE market is estimated at approximately $4 billion dollars and growing at 8% per year. finance.yahoo.com
NASDAQ:AREC
by AlenCiken
2
100% Survival Achieved in Osteosarcoma Lung MetastasesMoleculin Announces 100% Survival Achieved in Osteosarcoma Lung Metastases Animal Model a preclinical study in animals demonstrated a potentially significant therapeutic benefit of Annamycin against metastatic osteosarcoma. Computerized tomography (CT) scans demonstrated that animals treated with Annamycin exhibited significant suppression of tumor growth and not a single death was observed in the treated animals, whereas significant tumor burden contributed to the rapid death of 90% of untreated animals. While the study continues, as of day 130, the survival rate for animals treated with Annamycin was 100%, compared with only 10% for untreated animals. Annamycin is a "next generation" anthracycline that has recently been shown in animal models to accumulate in the lungs at up to 34 times the level of doxorubicin, which may account for the 100% survival rate attained in this most recent osteosarcoma lung metastases study. Moleculin recently announced that the FDA has allowed the Company's request for investigational new drug (IND) status in order to study Annamycin for the treatment of soft tissue sarcoma metastasized to the lungs. In addition, the FDA granted Orphan Drug Designation for Annamycin for the treatment of soft tissue sarcomas. "We expect that one, and potentially two, clinical trials in sarcoma lung metastases should be up and running this year." finance.yahoo.com
NASDAQ:MBRX
by AlenCiken
Space launch company Astra to go public via merger with SPAC HOLastra-to-become-the-first-publicly-traded-space-launch-company-on-nasdaq-via-merger-with-holicity BlackRock-managed funds and accounts lead investment in Astra to launch a new generation of space services to improve life on Earth. The transaction reflects an implied pro-forma enterprise value for Astra of approximately $2.1 billion. Upon closing, the transaction is expected to provide up to $500 million in cash proceeds, including up to $300 million of cash held in the trust account of Holicity and an upsized $200 million PIPE led by funds and accounts managed by BlackRock. In December 2020, Astra joined a small, elite group of companies that have made it to space. With over 50 launches in manifest across more than 10 private and public customers, including NASA and DOD, Astra has booked over $150 million of contracted launch revenue. Astra will begin delivering customer payloads this summer and begin monthly launches by the end of this year. The proposed transaction, which is expected to be completed in the second quarter of 2021. astra.com
H
by AlenCiken
ANVS401 Improves Cognitive and Functional Outcomes in StrokeAnnovis Bio's Lead Candidate ANVS401 Improves Cognitive and Functional Outcomes in Stroke Mice Study data showing that a combination treatment using the Company's lead candidate ANVS401 and pifithrin after stroke improved mice locomotor activity and cognitive function more so than treatment with just one or the other agent. While both treatments yielded improvements in locomotor and cognitive function, the combined ANVS401/PFT- treatment proved able to enhance stroke-induced endogenous neurogenesis and improve the functional recovery in stroke animals. The combined treatment also significantly improved cognitive function more than the single treatment with PFT- alone. finance.yahoo.com
A
by AlenCiken
GSM Announces potential financing arrangements being discussedFerroglobe Announces Discussions with Ad Hoc Group of Noteholders and Key Financial Partners Ferroglobe PLC (the “Company”) entered into confidentiality agreements (the “Confidentiality Agreements”) with certain holders (the “Ad Hoc Group of Noteholders”) of the 9.375% Senior Notes due 2022 (the “Notes”) issued by the Company and Globe Specialty Metals, Inc., to facilitate discussions addressing the maturity of the Notes and the introduction of further capital to the Company. The key highlights of the potential financing arrangements being discussed between the AHG and the Company are as follows: A major recapitalization of the business with $100 million of additional liquidity which guarantees sufficient funding to implement the Company’s strategic plan $60 million of new super senior notes provided by existing Noteholders $40 million of new equity funding Significant extension of the Company’s debt maturity profile as a result of a par exchange of the Notes with new senior secured notes with a 5 year tenor Equity allocation of 3.75% to all supporting holders of the Notes facilitating greater alignment of all stakeholders with management on strategy and long-term value creation The Company is negotiating with key stakeholders, including its largest shareholder Grupo Villar Mir, S.A.U., the injection of equity that is required to implement the proposed plan and is aiming to enter into a binding agreement with the Ad Hoc Group of Noteholders and equity providers reflecting the outcome of the discussions as soon as possible (although no assurance can be made that the discussions will be successful or that the new funding will be implemented). The contemplated financings offer Ferroglobe a stronger balance sheet and incremental capital which, in turn, provide a sound foundation for transforming the Company. the Company has been diligently evaluating various refinancing options to address its senior notes, alongside raising incremental capital. Collectively we are working towards a comprehensive financing that eliminates near-term refinancing risks, providing greater operational flexibility, and secures cash for the implementation of our plan. finance.yahoo.com
NASDAQ:GSM
by AlenCiken
This Penny Stock NMTR Could soar 462% in 2021The company’s development pipeline features drug candidates under investigation as treatments for short bowel syndrome (SBS) and celiac disease (CeD), two conditions that are both dangerous and difficult to treat. 9 Meters’ flagship product, Larazotide, is in Phase 3 development for the treatment of CeD. CeD affects about 1% of the population, yet there are no approved therapies. Top-line data from the study is expected in the second half of 2021. Furthermore, this past December, the company announced that it had entered an agreement with EBRIS, the European Biomedical Research Institute of Salerno, to investigate Larazotide as a potential treatment for respiratory complications due to COVID-19. The other major drug in the company’s pipeline is NM-002, for SBS. The company has recently announced positive Phase 1b/2a results, with a measurable impact on disease symptoms from a compound that was well-tolerated by patients. ne of these NMTR bulls is Truist’s Srikripa Devarakonda. Citing Larazotide as a key component of his bullish thesis, the analyst noted, “We acknowledge investors are likely to see a pivotal trial in a tough-to-crack Celiac disease program as high risk despite encouraging Ph2b data. We model $705M/$353M in peak unadjusted/adjusted sales and see potential upside of 400% - 1650% from positive Ph3 readout.” finance.yahoo.com
N
by AlenCiken
Silver Lake cashes out on AMC for $713 million after Reddit-fuelBuyout firm Silver Lake disclosed on Friday that it sold its stake in AMC Entertainment Holdings for $713 million this week, capitalizing on a 10-fold rise in the price of the shares as traders organizing on social media platforms such as Reddit snapped them up. The trade puts Silver Lake and its co-investors in the black following a $600 million convertible bond investment that the private equity firm made in AMC in 2018. Such an outcome looked unlikely when AMC, the world's largest movie theater chain, was battling to stave off bankruptcy last summer, a move it avoided thanks to a debt restructuring deal with Silver Lake and its creditors. Silver Lake was able to convert the bonds into shares thanks to the rally pushing AMC's stock above the bonds' conversion price this week. AMC stock price surged as traders targeted heavily shorted stocks . Silver Lake sold its stake over several open-market transactions that day, according to regulatory filings. AMC itself also capitalized on the rally. It raised $304.8 million by selling shares this week. It is considering new moves to raise capital through stock sales, sources told Reuters on Thursday.
NYSE:AMC
by AlenCiken
3
SIEB Soars as Reddit Feed Targets Another Short SqueezeBrokerage Firm Siebert Soars as Reddit Feed Targets Another Short Squeeze SIEB spiked Friday after the brokerage firm became the latest stock to attract the attention of ordinary investors prompted by a Reddit message board called WallStreetBets. Siebert, which does retail brokerage business through its Muriel Siebert subsidiary, said that it has not released any news on Friday, Dow Jones reported. WallStreetBets has been trying to collectively push shares of these companies higher in a bid to force hedge funds and other large investors to abandon their short positions -- bets that stock prices will decline -- in those companies. www.thestreet.com
NASDAQ:SIEB
by AlenCiken
2
$MRNA Gapping up into our Elliottwave 5th wave Target ZoneJust a quick video pre-market to show the massive gap up on our MRNA stocks swingtrading opportunity. The mantra to go away with today is "You Gotta Be In It To Win It" With a simple and repeatable stocks swing trading strategy, when all your requirements are met, you need to keep adding the trades as you will get these types of moves. Not everytime but "You Gotta Be n It To Win it!" Just keep putting the high probability trades through with the help of our elliottwave indicator suite
NASDAQ:MRNA
by xBratSoftwareSolutions
3
SPY perspectives - two scenariosWe are moving into a more and more tight price action as we are in the end of the wedge now and with the rise of volumes we see some heighten activity in trading. RSI and MACD divergence are still showing divergence with the price and RSI is almost below 50. MACD has a bearish crossing and the histogram is going negative. Two possible scenarios are forming now. We have a bullish one that is currently forming as we've jumped from the internal support around 373 price zone. Failing to continue the movement back inside the uptrend we may see a fall below 373 and move towards the first support zone at 360.
AMEX:SPY
by DailyChartist
Why GSX stock soared? Short-sellers are getting squeezed.......The coronavirus is getting worse in China, and it's possible that investors believe that's a good thing for GSX. GSX is a remote-education company in China, and its business grew substantially in 2020. And if COVID-19 gets worse in that country, it's possible 2021 will be another good year for this business. According to The Associated Press, new coronavirus cases are causing the Chinese government to lock down two hospitals in Shanghai. it appears investors might expect GSX Techedu's services will be in greater demand if the pandemic worsens in China. This is further complicated by short interest in this stock. According to Yahoo! Finance, around half of the stock's float was sold short up until recently. If investors are buying shares over the last few days because of the news coming out of China, it could be causing a short squeeze, as short-sellers are forced to cover their bearish positions. Over 22% of GSX stock is sold short, giving it a short interest ratio of almost 14 days (anything over seven days is considered a lot). While that indicates short-sellers are getting squeezed, or being forced to cover their positions at ever-higher prices, it's more just a phenomenon flooding the market at the moment. the company is under fire from many popular short-sellers, who claim GSX Techedu is a fraud. And the company has indeed admitted that it is under investigation from the Securities and Exchange Commission (SEC). While that investigation is ongoing and it may turn out that everything is above board, this has caused a lot of people to actively bet against this stock. The company faces the possibility of being delisted from major U.S. exchanges if the SEC finds wrongdoing. Therefore, it's important to approach a GSX Techedu investment fully aware of this risk. Investors shouldn't be swayed by these price swings, and investors would be smart to sit on the sidelines until GSX Techedu sorts out the battle taking place between short-sellers and those long on its stock. www.fool.com
G
by AlenCiken
Overstock to be limited partner in blockchain fundOverstock Partners with Pelion Venture Partners to Oversee Medici Ventures’ Blockchain Assets Overstock to be limited partner in blockchain fund OSTK today announces it will be converting Medici Ventures, Inc., its wholly owned blockchain-focused subsidiary, to a limited partnership (the “Fund”). An entity within Pelion Venture Partners, a third-party venture capital firm with a proven track record of successfully investing in early stage companies, will act as the general partner of the Fund. Pelion has blockchain and technology expertise with early stage companies and has helped guide many companies to economic success. Under the arrangement, which will close after obtaining necessary legal and regulatory approvals, Medici Ventures will be converted into a limited partnership. finance.yahoo.com
O
by AlenCiken
Bank of America in risk of a trend reversalMy bearish view for Bank of America is almost confirmed. All is left is a move below $30.59 zone. RSI and MACD are flashing red and point for a continuation of the selling. Volumes are descending as activity is slowing down resent days. Since the bad earnings, the bank is under pressure from investors, but still the downtrend is not entirely confirmed. Given the broader market and perpetual stimulus, BAC may have a second chance to continue its uptrend.
NYSE:BACShort
by DailyChartist
PBI jumps on positive pitch from Seeking Alpha contributorPitney Bowes jumps on positive pitch from Seeking Alpha contributor Pitney Bowes (NYSE:PBI) gains 40% after a Seeking Alpha contributor writes that the stock is "significantly" undervalued vs competitors and a break up or sale of company would unlock value. Expects PBI's global e-commerce business to be profitable for first time ever when earnings are released on Feb. 2. Highlights that Legendary investor Bill Miller owns PBI and believes e-commerce segment on a standalone basis is worth $12/share, citing 3Q Miller investor letter. PBI short interest "nearly" 20% of float www.reddit.com
NYSE:PBI
by AlenCiken
4
Significant and Rapid Reduction in Hepatitis B Surface AntigenInitial Data from Ongoing Phase 1 Trial of VIR-3434 for Chronic Hepatitis B Virus Infection Demonstrates Significant and Rapid Reduction in Hepatitis B Surface Antigen Data from the first blinded cohort of eight patients, two of whom received placebo and six of whom received a single dose of 6 mg of VIR-3434, showed that six of eight patients achieved a mean reduction of 1.3 log10 IU/mL in serum hepatitis B virus surface antigen (HBsAg) by day eight, the day when nadir was achieved in most patients. Additional data will be submitted for presentation at an upcoming medical conference. A Phase 2 trial combining VIR-3434 with Vir’s HBV-targeting siRNA, VIR-2218, is expected to commence in the second half of this year. finance.yahoo.com
NASDAQ:VIR
by AlenCiken